BOFAS 2023 Video Recap BOFAS 2023 Video Recap Now Live for Members who attended the conference 19 May 2023 If you are a BOFAS member who attended the 2023 annual congress, you can now access the full video recap of the conference here. Read more
BOFAS 2024 - Belfast BOFAS 2024 - Belfast 6th to 8th March 2024 15 March 2023 BOFAS 2024 will be held in Belfast from 6th to 8th of March Read more
Website Updates Website Updates Research Grants and Email Patient Info Leaflets 31 March 2022 The research grants page has been updated and a list of previous grants can now be viewed. Patient information pages now have a link so that the page link can be shared with patients via email. Read more
2Oct2025 BOFAS Principles Course - Dubai 02/10/2025 - 04/10/2025 Read more The aim is to give Overseas Trainee Orthopaedic Surgeons a solid grounding in the principles and the decision making in Foot & Ankle Surgery. There is an emphasis on clinical examination of cases, small group discussions and learning surgical approaches in the cadaver lab. This is the first course BOFAS is running in UAE and the aim is to expand the Foot and Ankle education and training in the Middle East and Gulf area. Venue - Le Meridien, Dubai, United Arab Emirates Documents to download ACv3BOFAS-Principles-Course-Programme-DXB(.pdf, 2.13 MB) - 540 download(s) Read more
20Oct2025 BOFAS Principles Course Taunton 20/10/2025 - 21/10/2025 Read more These courses are aimed at Higher Surgical Trainees / ST3 onwards and are designed to teach the core of Foot and Ankle surgery in an informal and interactive environment. The emphasis is on clinical examination cases, discussion groups and typical day-to-day clinic scenarios. Although not an exam preparation course, content is taught to the standard expected in the FRCS(Tr & Orth) exam; that of a day-one non-specialist orthopaedic consultant. Applications will open on 1st September 2023. Venue - Taunton (TBC) Documents to download BOFAS-Course-Programme--Taunton-2025(.docx, 31.88 KB) - 768 download(s) Read more
Karan Malhotra / 14 February 2021 / Categories: Abstracts, 2021, Poster DVT and Achilles tendon rupture - a better pill to swallow? G. Scott, A. Biggs, A. Carne, M. Rogers, M. Solan Background: The BOFAS Guidance regards Achilles rupture patients as particularly high risk for VTE. Many hospitals use 6-weeks of low molecular weight heparin (LMWH) injections which are unpleasant for patients and result in reduced compliance. An extended course of prophylaxis is advised following hip and knee arthroplasty, however Novel Oral Anti-Coagulant (NOAC) tablets are licensed. We offered Rivaroxaban to our Achilles patients as an alternative. Since this is “off-license”, we developed an information sheet and consent form. In this study we compared VTE prophylaxis outcomes in our Achilles rupture patients. Methods: We retrospectively reviewed patients diagnosed during three different periods between 2010 and 2019. During the first patients were treated in any fracture clinic. Chemical prophylaxis was not always prescribed. In the second period patients were triaged to a Foot & Ankle clinic. VTE prophylaxis was universal but not standardised. The third period saw patients managed by one F&A surgeon using the Rivaroxaban protocol. Thromboembolic event or significant bleeding within 3 months of treatment were recorded outcomes. Results: Two hundred and thirty patients with Achilles tendon rupture were identified. Thirty-one were excluded because they took anticoagulants already or had a DVT on initial USS. There were no secondary bleeding episodes or fatal PEs. Forty patients had no prophylaxis and 7.5% of these developed a symptomatic DVT or PE. Of the 80 patients managed with LMWH, 6.25% suffered a thromboembolic event. A total of 79 patients were given Rivaroxaban and zero suffered a DVT or PE. Conclusion: Numbers here are small, but suggests Rivaroxaban is an appropriate alternative to LMWH. Poor compliance due to pain and bruising from injections isn't relevant with a tablet that also doesn't require any patient/family education. Rivaroxaban has led to improved VTE rates for patients with Achilles tendon rupture in our hospital with no complications. Print 6014 Tags: AchillesVTE Documents to download P1 G Scott BOFAS Poster Submission(.pdf, 140.93 KB) - 1512 download(s)